Can a cholesterol drug stop a heart valve from hardening?
NCT ID NCT07256197
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether a drug called a PCSK9 inhibitor (Tafolecimab) can slow the progression of mild to moderate calcific aortic stenosis, a condition where the heart valve narrows and hardens. Researchers will give the drug to half of 160 participants and compare changes in valve function over time. The goal is to find a medication that can delay or prevent the need for valve replacement surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PCSK9 inhibitors (Tafolecimab)
What this could lead to
If it works, this could point toward a drug treatment to slow or prevent worsening of aortic stenosis, potentially delaying or avoiding valve surgery.
What could go wrong
This is a relatively small phase 3 trial (160 people) and has not started recruiting. The drug may not slow the disease, and side effects from PCSK9 inhibitors are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS, CALCIFIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Anzhen Hospital, Capital Medical University
Beijing, Beijing Municipality, 100029, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact